The impact of omega-3 fatty acids (FA) on systemic inflammatory responses has been demonstrated in a number of dietary and epidemiologic studies. A recent editorial in Joint Bone Spine by Olfa Saidane1 and colleagues suggests a prophylactic role of Omega-3 FAs in the possible prevention of inflammatory diseases such as rheumatoid arthritis (RA).
A recent study published in Medicine highlights the top 100 articles focused on rheumatoid arthritis that have revealed the most data. Learn more in this article.
The JAK1 inhibitor will be considered as a marketed once-daily therapy for moderate to severe RA in the second half of this year.
Despite years of research that show omega-3 fatty acids from specific fish species can improve rheumatoid arthritis (RA) symptoms and even protect at-risk patients from developing RA, a new study of 3,863,909 person-years published in BMC Musculoskeletal Disorders finds no benefit.
The benefits of exercise to combat the effects of musculoskeletal conditions have been well-documented. Take this quiz to test your knowledge of sports and exercise medicine in rheumatology.
An assay designed to track TNF counts in recently-treated RA patients found that early reduction of the protein could indicate future problems for the patient.
ABP 798, a biosimilar candidate for rituximab, met pharmacokinetic, efficacy, and safety endpoints in a trial among participants with rheumatoid arthritis.
Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.
The investigators used FDG PET-CT to detect myocardial inflammation in RA patients without clinical heart failure.
Researchers identify influential factors on hand function in rheumatoid arthritis.
This study appears to confirm the role of B cells in the early pathogenesis of RA and sheds light on an avenue for further investigation.
The interaction of anticitrullinated protein antibody and rheumatoid factor may foretell the response to treatment in patients with rheumatoid arthritis.
Here: 5 challenging questions to test your knowledge.
The smaller, incomplete study is looking into both the efficacy and safety of the longtime therapy for patients with RA.
Scroll through the slides for a review of the many options available to help reduce pain and improve function.
The ACTPen was approved on the basis of a pair of clinical trials presented at the 2018 American Society for Clinical Pharmacology & Therapeutics Annual Meeting.
Flares of rheumatoid arthritis have been linked to higher disease activity, lower quality of life, and increased radiographic progression.
Speaking ambitiously, determining the right tests and initial therapies for patients with rheumatoid arthritis could become optimized.
Belgian researchers sought to determine which patients are appropriate candidates for tapering biologics. In this article, we summarize their findings.
How will you respond to patients who ask about treating rheumatoid arthritis with cannabinoids?
What next when methotrexate monotherapy fails? The answer-and 4 more questions on RA treatment-can be found here.
Recent findings allay concerns about increased costs and rates of adverse events related to TTT strategies.
What’s new: biologic tapering, high-dose influenza vaccine, real-time patient input.
New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.
A strategy to boost the immune response to vaccination in patients with seropositive rheumatoid arthritis.
